Plain-English translation of NCT05630586 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This is a Phase 2 trial testing , a medication given by injection, in patients who have just had an acute ischemic stroke (a type of stroke caused by a blood clot). Researchers want to see whether giving this medication in the first few hours after stroke can help protect the brain and improve recovery. The study will compare people who receive the medication plus standard stroke care to people who receive standard care alone.
After a stroke, brain damage happens very quickly, and current treatments have limits in how much recovery they can help achieve. This medication may have protective properties that could reduce brain injury and improve outcomes if given very soon after stroke occurs.
You likely qualify if…
You likely don't qualify if…
If you qualify and enroll, you will receive either the new medication by injection once weekly for 4 weeks along with standard stroke care, or standard stroke care alone. You'll need to be hospitalized for acute stroke treatment, and then continue receiving either the study medication or standard care over the following weeks. The trial will track your recovery and safety throughout this period.
AI-generated summary from trial data · Jun 1, 2026 · Not medical advice
Denmark
Sponsor
Aarhus University Hospital
Collaborators
Bispebjerg Hospital, Glostrup University Hospital, Copenhagen
Enrollment target
~380 participants
Started
April 2023
Primary completion
September 2025
This trial's estimated completion date has passed — the record may not be fully up to date.
Age range
18 Years and older
Last updated on clinicaltrials.gov in April 2023.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Thomas Mellemkjaer, MD
Aarhus University Hospital
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.